Pfizer starts work on new biologics clinical manufacturing facility

16 June 2016

US pharma giant Pfizer (NYSE: PFE) today broke ground for its new biologics clinical manufacturing facility in Andover, Massachusetts.

Expanding the company’s presence in the state, Pfizer will invest more than $200 million in development of the 175,000 sq ft state-of-the-art facility that will enable the production of high-quality, complex biologics and vaccines. The new 5-story building is expected to be operational by January 2019. Around 75 new employees will be hired to support clinical manufacturing. In addition to the Andover campus, Massachusetts is home to Pfizer’s Research and Development hub in Cambridge. Pfizer has about 2,000 employees based in Massachusetts.

“The expansion of Pfizer’s presence in Andover will provide state-of-the-art manufacturing to help bring new medicines and vaccines to the patients we serve,” said John Ludwig, senior vice president, BioTherapeutics Pharmaceutical Sciences in Pfizer R&D.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK